Novo Nordisk Acquires Prothena’s PRX004, Plus Full ATTR Program

Novo Nordisk Acquires Prothena’s PRX004, Plus Full ATTR Program

299853

Novo Nordisk Acquires Prothena’s PRX004, Plus Full ATTR Program

Novo Nordisk has acquired Prothena’s clinical-stage antibody PRX004, an investigational therapy for people with hereditary transthyretin amyloidosis (ATTR), which also includes familial amyloid polyneuropathy (FAP), as well as other non-hereditary forms of the disease. While the company initially will focus on developing PRX004 for the treatment of ATTR cardiomyopathy — a form of the disease that mainly affects the heart — Prothena’s broader ATTR amyloidosis research program also is part of the acquisition deal. That…

You must be logged in to read/download the full post.